Enacted precedent
What Montana's Universal Right to Try law does
Montana SB 535 creates a licensed, supervised path for eligible patients to consider experimental treatment after reviewing approved choices with a treating clinician. Niklas Anzinger and Infinita led the push for the law, and Infinita formed the state's first experimental treatment review board.
Read the enrolled SB 535Patients can reach treatments, and providers can deliver them
Montana removed the terminal-illness restriction in 2023. In 2025, SB 535 created licensed experimental treatment centers, direct provider-patient payment agreements, outcome monitoring, adverse event reporting, and an access requirement funded by 2% of each center's net annual profits.
2015
Right to Try begins
Montana creates an initial access path for eligible patients.
2023
SB 422 broadens eligibility
The state removes the terminal-illness restriction from its Right to Try law.
2025
SB 535 creates licensed centers
The law defines experimental treatments and sets state licensing, safety, consent and oversight requirements.
2026
The doors can open
Final rules take effect, and Montana publishes the experimental treatment center application.
What the law requires
Licensed centers
Experimental treatment centers must obtain a state license and operate within Montana's facility rules.
Clinical review
A treating health care provider identifies the patient as eligible after considering approved options.
Written consent
The patient receives the treatment's possible outcomes, approved alternatives, insurance limits, and costs.
Safety and records
Centers must meet professional, safety, recordkeeping, inspection, and reporting requirements.
Professional accountability
Licensing boards keep authority over professional conduct and care provided under the law.
A broader treatment definition
The statute covers drugs, biologics, devices, procedures, and individualized treatments that meet its conditions.
This is already happening
Rules in force
The operating rules for experimental treatment centers took effect July 25, 2026, with an independent review board evaluating treatments.
$12,500 to apply
A company with a drug through preliminary safety testing pays $12,500 to ask the review board for approval to offer it in Montana.
First applications filed
Treatments for neuropathy and hearing loss are already under review. The first licensed clinics are expected around the end of 2026.
The Montana Experimental Treatment Review Board is taking submissions
Infinita formed this independent board of physicians, scientists and ethicists. It reviews treatments that have passed Phase I for Montana's centers, and it has issued its first decision.
Reported by MIT Technology Review (July 30, 2026).
How the act builds on Montana
Montana showed that a state can open access to promising treatments. The Care-Integrated Clinical Trials Act builds on it. Patients get screened treatments through their own doctor's practice as well as at dedicated centers. Every patient's outcome is recorded, and each protocol's yearly public report must include failures. And doctors can enroll patients in randomized trials during ordinary care, so the next patient chooses better.
Organizations in Montana
Patient groups, clinics, hospitals and researchers in Montana can join the Care to Cures Alliance, or partner with us.